Hericenones And Erinacines: What The Research Actually Did
Hericenones and erinacines are two families of small molecules isolated from the mushroom Hericium erinaceus, and the research on both is almost entirely cell-culture and rodent work. Hericenones come from the fruiting body; erinacines come from the mycelium, the thread-like growth stage. That split matters more than anything else here: the two bodies of literature are not interchangeable, and the supplements made from each are not the same material.
The category flattens all of this into one line about nerve growth factor. Read the hericenones and erinacines research itself and you find reviews that disagree about whether hericenones do anything in a dish, concentrations in the millimolar range, and human trials that never measured nerve growth factor once.
Two families, two parts of the mushroom
A 2025 systematic review of preclinical models in Frontiers in Pharmacology describes hericenones as found exclusively within the fruiting bodies of the mushroom, and erinacines as mainly mycelial. It counts erinacines A to C, H and I among the compounds reported to stimulate nerve growth factor synthesis in vitro, and notes this happened only when they were applied to glial cells — the support cells of nervous tissue — not to neurons directly. Fifteen erinacines, labelled A to K and P to S, had been identified by the time of a 2018 review in Behavioural Neurology. Erinacine A is the one most studied.
Then the disagreement. The 2018 review states that hericenones did not stimulate nerve growth factor gene expression in rat astroglial cells or in human astrocytoma cells, and uses that to argue hericenones are not the compounds of interest. The 2025 review lists hericenones A to H among the in-vitro stimulators. Same compound family, two reviews, opposite readings. Anyone quoting a single confident sentence has picked a side without telling you.
What the experiments actually did
The 2018 review's own table reports nerve growth factor synthesis in cell studies mostly at concentrations between 1 mM and 70.8 mM, with erinacine A inducing roughly 250 pg/ml at 1 mM. Millimolar is a laboratory concentration applied to cells in a dish. Nobody eats a dose like that, and the review draws no line between the two.
The rodent work is better described. In APPswe/PS1dE9 transgenic mice, erinacine-enriched mycelia were given orally for 30 days from five months of age at 300 mg/kg, with erinacine A or S at 30 mg/kg. In rats, erinacine A-enriched mycelia at 50 and 300 mg/kg for five days were reported to reduce infarct volume after induced ischaemia by 22% and 44%.
The 2025 review is blunt about the limits. It provides no translation of animal doses to humans, and notes confusion over whether a stated dose means dry mycelium or final extract. Strains, growth conditions and extraction methods often go unreported, and erinacines are frequently not quantified at all, which the authors call a limit on reproducibility. They add that the binding targets remain unknown and that most in vivo studies used only male animals.
The human trials did not measure nerve growth factor
Two human trials are quoted constantly here. Neither measured nerve growth factor in a participant.
Mori and colleagues, in Phytotherapy Research in 2009, ran a double-blind, placebo-controlled trial in 30 Japanese adults aged 50 to 80 with mild cognitive impairment, of whom 29 were analysed. Participants took twelve 250 mg tablets a day for 16 weeks — 3,000 mg of tablet mass, each tablet 96% dried fruiting-body powder — then four weeks off. Scores came from a 30-point scale the authors built themselves from the Revised Hasegawa Dementia Scale plus a clock-drawing item. They state the active ingredients and mechanism were not determined, their hericenone explanation was speculative, and the placebo group's own rising scores may reflect habituation.
Docherty and colleagues, in Nutrients in 2023, ran a double-blind, placebo-controlled pilot in healthy adults aged 18 to 45: 43 randomised, 41 analysed at day 29, three 600 mg capsules each morning for a mean of 28.5 days. The authors call it a small pilot, likely underpowered, needing replication, with no human bioavailability data to tell them when to sample. The paper does not specify whether the material was fruiting body or mycelium, extract or powder — the distinction that decides which compound family is even present.
Reading a label against this literature
| What the label says | Which literature it belongs to | What is usually missing |
|---|---|---|
| Fruiting body extract | Hericenone work (fruiting body) | Any hericenone assay at all |
| Mycelium, or mycelium on grain | Erinacine work (mycelium) | Erinacine quantification; grain share of weight |
| 10:1 extract | Neither — it is a ratio, not a compound | What was concentrated, and measured against what |
| "NGF" on pack or page | In-vitro and rodent only | Any human measurement of it |
For taxonomy first, see what Lion's Mane actually is, and what Cordyceps is for the other mushroom in the tube. The full set sits in our guides index.
What is in a Chaski tube
A tube holds 600 g of 77% dark chocolate buttons. The listed components are single-origin Peruvian and Ecuadorian cacao, coconut sugar, Lion's Mane as a fruiting body extract, Cordyceps sinensis as mycelium, and Ginkgo Biloba, which is in the process of being replaced by 200 mg of Tremella fuciformis (10:1 fruiting body extract) per daily dose. No emulsifiers, no seed oils, no palm oil, no added cane sugar. The cacao is low-temperature ground. Every batch is tested for lead, cadmium and pesticides. The daily dose on the pack is four buttons.
Two limitations follow from the sections above, and they cut against us. The Lion's Mane here is a fruiting body extract, so the erinacine literature — mycelium work — describes different starting material. And we hold no hericenone or erinacine assay for the extract we buy, so we cannot give you a figure, and nothing here should be read as one. The full component list is on the Chaski Cacao page.
Frequently Asked Questions
Are hericenones and erinacines the same thing?
No. They are separate compound families from the same mushroom species, and they are found in different parts of it. The 2025 systematic review in Frontiers in Pharmacology describes hericenones as occurring exclusively in the fruiting body, and erinacines as mainly mycelial. The 2018 Behavioural Neurology review reports that the fruiting body was found to contain no erinacines at all, which is why the authors of that paper propose submerged fermentation to grow mycelium enriched to at least 3 mg of erinacines per gram. Because they come from different material, a product made from one does not contain meaningful amounts of the other.
Has nerve growth factor ever been measured in a human taking Lion's Mane?
Not in either of the two trials most often cited. Mori and colleagues, in Phytotherapy Research in 2009, measured scores on a 30-point cognitive scale in 30 adults aged 50 to 80 and took no nerve growth factor measurement from any participant. Docherty and colleagues, in Nutrients in 2023, measured cognitive tasks, mood and stress scales in 43 young adults and did not measure nerve growth factor or brain-derived neurotrophic factor either. In both papers nerve growth factor appears only in the discussion, as a proposed mechanism drawn from cell and rodent studies.
What concentrations were used in the cell studies?
The 2018 review in Behavioural Neurology tabulates nerve growth factor synthesis in cell studies mostly at concentrations between 1 mM and 70.8 mM, and reports erinacine A inducing around 250 pg/ml of nerve growth factor at 1 mM. Those are concentrations applied directly to cultured cells in a laboratory, not amounts consumed by a person, and neither that review nor the 2025 systematic review in Frontiers in Pharmacology offers a conversion between the two. The 2025 review states plainly that it provides no translation of animal doses to human ones.
Why do reviews disagree about hericenones?
Because the underlying cell experiments used different cell types and read out different things. The 2018 Behavioural Neurology review reports that hericenones failed to stimulate nerve growth factor gene expression in rat astroglial cells or human astrocytoma cells. The 2025 Frontiers in Pharmacology review lists hericenones A to H among compounds reported to stimulate nerve growth factor synthesis in vitro. The 2025 review also notes that strains, growth conditions and extraction methods frequently go unreported across this literature, and that erinacines are often not quantified, which it treats as a limit on reproducibility.
Sources
- Spangenberg ET et al., Frontiers in Pharmacology, 2025 — systematic review of preclinical models.
- Li IC et al., Behavioural Neurology, 2018 — narrative review of cell and rodent studies.
- Mori K et al., Phytotherapy Research, 2009 — randomised, double-blind, placebo-controlled trial.
- Docherty S, Doughty FL, Smith EF, Nutrients, 2023 — randomised, double-blind, placebo-controlled pilot trial.
See what is in the tube
Chaski Cacao — 600 g tube, 77% dark, batch-tested for lead, cadmium and pesticides